Advertisement
UK markets open in 5 hours 38 minutes

  • NIKKEI 225

    38,578.85
    -341.41 (-0.88%)
     

  • HANG SENG

    19,376.53
    0.00 (0.00%)
     

  • CRUDE OIL

    79.18
    -0.05 (-0.06%)
     

  • GOLD FUTURES

    2,381.50
    -4.00 (-0.17%)
     

  • DOW

    39,869.38
    -38.62 (-0.10%)
     

  • Bitcoin GBP

    51,528.12
    -700.86 (-1.34%)
     

  • CMC Crypto 200

    1,375.85
    -18.19 (-1.30%)
     

  • NASDAQ Composite

    16,698.32
    -44.07 (-0.26%)
     

  • UK FTSE All Share

    4,594.70
    -2.01 (-0.04%)
     
money:

Best UK mortgage deals of the week

Find out the latest mortgage rates and deals from HSBC, NatWest, Santander, Barclays and more

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

Business Wire
·2-min read

WALTHAM, Mass., April 29, 2024--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will host a webcast and conference call on Wednesday, May 8 at 8:00 a.m. ET to discuss its first quarter 2024 financial results and recent business highlights.

The webcast can be accessed under "Events and Presentations" on the Investors section of the Viridian website at viridiantherapeutics.com. To participate in the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference code 7373356. A replay of the webcast will be available following the completion of the event.

About Viridian Therapeutics

Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.

ADVERTISEMENT

Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential first- and best-in-class subcutaneous therapy for the treatment of TED.

In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Viridian is based in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com. Follow Viridian on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240428139202/en/

Contacts

Louisa Stone, 617-272-4604
Manager, Investor Relations
IR@viridiantherapeutics.com